The FDA approved zidesamtinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). LCRF Chief Scientific Officer Dr. Antoinette Wozniak explains why this development is important. #LungCancer LCRF.org/z4r1

Zidesamtinib for ROS1+ NSCLC - Lung Cancer Research Foundation

The good news The U.S. Food and Drug Administration (FDA) approved zidesamtinib for adults with locally advanced or metastatic ROS1-positive (+) non-small cell lung cancer (NSCLC) who received a…

lungcancerresearchfoundation.org

Team TRG gearing up for the Free to Breath Chicago Walk! #ButterflySummer #FreetoBreathe #ChicagoWalk www.teamtrg.com

#LungCancer connects us. Finding a cure unites us. Share your butterflies and your connection. 🫁 🦋 🤍 🩵 💙 💛 #ButterflySummer #WLCD

#LungCancer connects us. Finding a cure unites us. Share your butterflies and your connection. 🫁 🦋 🤍 🩵 💙 💛 #ButterflySummer #WLCD

#FlashbackFriday to the community, awareness, and support you've built for #LungCancer research in Kansas City! This year's Free to Breathe Kansas City Walk will take place Saturday, September 26 at Longview Lake Shelter. Hope to see you there! LCRF.org/KC 🦋 🫁

#FlashbackFriday to the community, awareness, and support you've built for #LungCancer research in Chicago! This year's Free to Breathe Chicago Walk will take place Sunday, October 18 at Montrose Harbor. Hope to see you there! LCRF.org/Chicago

Every Wednesday, we spotlight women who are making a difference in the lung cancer community. Stephanie is one of those women. She leads the Free to Breathe Kansas City Walk committee, giving her time and energy to support research in honor of her dad. #WomenWednesday LCRF.org/women

Incredibly proud of the work that LungCAN members are doing to bring patient needs to the fore. LCRF's Sr. Director of Research Programs, Dr. Dhru Deb, served on the research committee, led by Lisa Spain, MEd, of Rexanna's Foundation, that produced these findings.

How to Support Patients With Lung Cancer | www.PhysiciansWeekly.com

“From the very beginning, care needs to be a comprehensive but individualized effort,” says Lisa Spain, MEd.

physiciansweekly.com

LCRF's Beth Zaberdac is among the expert speakers in a free patient webinar, Non-Small Cell Lung Cancer, on Monday, July 27 at 11 am ET. The webinar is presented by the National Comprehensive Cancer Network. First 150 RSVPs also get a free NCCN Guidelines for Patients®. NCCN.org/patientwebinars

Every #WomenWednesday, we are spotlighting women making a difference – in labs, at hospitals, and by sharing their stories. Rose is living with #LungCancer and wants you to know that this disease can touch even a marathon runner like her, without any known risk factors. LCRF.org/women

Did you hear about the 7-year results from the CROWN trial, which were presented at ASCO's annual meeting? LCRF Chief Scientific Officer Dr. Antoinette Wozniak explains what was found and what it means going forward. #LungCancer #ASCO2026 LCRF.org/smsc7

CROWN Trial: 7-year update - Lung Cancer Research Foundation

The good newsThe 7-year outcomes of the CROWN Trial were presented at the annual American Society of Clinical Oncology (ASCO) meeting. Why it’s importantLorlatinib is a third generation ALK-tyrosine…

lungcancerresearchfoundation.org

#ICYMI #ScienceMadeSimple #ASCO2026 - The plenary session of ASCO's 2026 annual meeting featured three presentations which could impact #LungCancer treatment. LCRF's Chief Scientific Officer, Dr. Toni Wozniak, explains what this means. LCRF.org/sms26ASCO

Work presented at ASCO meeting could impact lung cancer treatment - Lung Cancer Research Foundation

The good newsThree of the top five presentations at the plenary session of the annual ASCO meeting could potentially impact lung cancer treatment. These presentations typically spotlight major…

lcrf.org

Every #WomenWednesday, we spotlight those making a difference in the #LungCancer community – in labs, at hospitals, and by sharing their stories. Women like Aria Vaishnavi, PhD, a researcher working to understand oncogene-driven disease progression and radon-induced lung cancer. LCRF.org/women

Rosee was blindsided by her #LungCancer diagnosis in 2024. She has found strength in becoming an advocate herself, educating others about early detection, supporting fellow patients, and staying engaged with advances in research. Read her story: LCRF.org/rosee #SaturdayStrong

Did you know? LCRF just released a RFP to accelerate breakthroughs in ALK+ #LungCancer research. This important work is only possible because of incredible supporters like Sweat For Breath Foundation, whose partnership and advocacy continue to fuel meaningful progress for patients and families. 🙏

LCRF's spring e-news is out! If it's not in your inbox, catch up on grants, RFPs, Science Made Simple, Connecting the Dots, ASCO happenings and more at LCRF.org/enews. (And be sure to subscribe: LCRF.org#subscribe) #LungCancer #InTheNews

LCRF Spring 2026 enews

lcrf.org

#LungCancer investigators: LOIs are being accepted for 3 new grant mechanisms. A $300K 2yr award supports ALK+ NSCLC research. LCRF & AstraZeneca partnered on two SCLC-focused grants: a $500K 3yr award on treatments & a $250, 2yr award to improve outcomes through patient advocacy. LCRF.org/funding

Research funding opportunities - Lung Cancer Research Foundation

LCRF offers lung cancer research funding opportunities. Read about current Requests for Proposals, deadlines, and requirements.

lcrf.org

LCRF and AstraZeneca announced that two research awards focused on improving outcomes for people with small cell #LungCancer (SCLC) are now open for investigator submissions. One award focuses on improving treatment; the other on improving the outcomes through patient advocacy. LCRF.org/sclc-rfp

LCRF and AstraZeneca announce open call for research proposals with focus on SCLC

lcrf.org

LCRF has announced a new research award focused on accelerating treatment options for people with ALK fusion-driven non-small cell #LungCancer is now open for investigator submission. This new grant was made possible through generous support from our community. LCRF.org/alk-rfp

LCRF announces request for proposals for ALK+ lung cancer research grant

lcrf.org

Dr. Jalal Ahmed recently published his LCRF-funded work on CAR T-cell therapy in #LungCancer. LCRF's Chief Scientific Officer, Dr. Antoinette Wozniak, explains the science of CAR T-cells and how this type of therapy can impact patient outcomes. LCRF.org/sms2664

CAR T-cell therapy for lung cancer - Lung Cancer Research Foundation

The good news Jalal Ahmed MD, PhD, an Assistant Professor at the Precision Immunology Institute, Department of Radiation Oncology, Icahn School of Medicine, Mount Sinai in New York City, has […]

lungcancerresearchfoundation.org

Scientists from the Francis Crick Institute in the UK were able to predict who would develop lung cancer more accurately than the best risk assessment models currently in use through identifying a set of proteins in the blood. From the NYT: buff.ly/xZI1UdV

Are you going to the ASCO Annual Meeting in Chicago? LCRF will be there this weekend! Visit us at the ASCO-Sponsored Patient Advocacy Booth (#13000) from May 30 - June 1. We'd love to share our #LungCancer resources and information with you.

We’re proud to announce our Women & Lung Cancer video event with Dr. Isabel Preeshagul and Dr. Narjust Florez. This is a compilation of highlights from our webinars on women and lung cancer over the past five years. Watch now! LCRF.org/women#video #LungCancer #WLC #Women

Get organized by making a plan that reflects your wishes to protect the people you love and support for LCRF. Create or update your will with our trusted partner, FreeWill, in just 20 minutes at no cost: frwill.link/lcrf_spring26

LCRF, in partnership with patients, survivors, caregivers, loved ones, industry partners and medical leaders, is funding two $300,000 two-year awards to accelerate treatment options for people with ALK positive NSCLC Read more about this collaborative effort. buff.ly/y5mA3NV

The 2026 ASCO Annual Meeting in Chicago starts May 29, and we're eager to find out what #LungCancer developments everyone will be talking about! Join our June 17 Together Separately livestream to hear from the experts, who will recap the conference. Sign up at LCRF.org/ASCO2026

Together Separately: ASCO recap - Lung Cancer Research Foundation

This livestream is an opportunity to connect face-to-face with others who care about lung cancer. Our guest experts will discuss developments coming out of this year’s ASCO Annual Meeting. Logan […]

lcrf.org

Nurses: Are you going the ONS Congress in San Antonio, TX May 13-17? LCRF will be there! Visit us at booth #347 – we'd love to share our #LungCancer resources and information with you.

A team led by Dr. John Heymach has been selected to receive the LCRF | Boehringer Ingelheim Team Science Award on Innovative Therapeutic Strategies to Understand and Treat Lung Cancers Harboring HER2 Mutations – a $1.5M award. LCRF.org/2025her2teamscience #LungCancer

LCRF | BI Team Science award

lcrf.org

In Dr. Dhru Deb's latest Connecting the Dots article, he reviews research advancements for KRAS-mutant non-small cell #LungCancer (NSCLC) – one of the most common (and most frustrating) drivers of lung adenocarcinoma. Dr. Deb is Senior Director, Research and Administration for LCRF. LCRF.org/CTD526

Connecting the Dots: from urgency to impact in KRAS-mutant lung cancer - Lung Cancer Research Foundation

By Dhru Deb, PhDSenior Director, Research and Administration, LCRF I wrote this article in response to a request from Enrico Peretti of Milan, Italy, who recently reached out to us […]

lcrf.org

This Women's Health Month, we're premiering a video featuring highlights from the past five years of Women and #LungCancer webinars with Dr. Narjust Florez & Dr. Isabel Preeshagul. Sign up and you'll be added to our exclusive group to get an email alert as soon as it goes live! mailchi.mp/lcrf/wlc

Sign up for the premiere!

mailchi.mp